Objective. Hepatocellular carcinoma (HCC) is frequently associated with visceral pain. Transcranial direct current stimulation (tDCS) has been proven to reduce chronic pain; however, its effectiveness in malignant visceral pain is unknown. This study aimed to investigate the effects of tDCS in patients with visceral pain due to HCC.
Introduction
Hepatocellular carcinoma (HCC) has become the third most common malignancy worldwide and the fourth highest cause of cancer-related deaths [1, 2] . More than 80% of cases and deaths due to HCC occur in developing countries [3] . In Africa, liver cancer has been ranked as the fourth most common cancer, and most liver cancers are HCC [4] . Pain management in patients with liver impairment is a challenge due to altered metabolism and effects of many drugs through a variety of mechanisms, including changes in pharmacokinetic behavior, altered accumulation of free drugs in plasma, and end-organ response [5] .
New neuroimaging tools have provided new insights into maladaptive structural and functional changes in V C 2017 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com the brain in patients with chronic abdominal pain. Recent data show that this disorder might be associated with a dysregulation at multiple levels of the socalled "brain-gut axis" [6] , involving both the central nervous system (CNS) and the peripheral nervous system (PNS). These changes include central hyperexcitability in pain-associated brain areas [7] [8] [9] [10] . These areas, comprising the cingulated gyrus, somatosensory cortex, and limbic system, build so-called "pain memory" [11, 12] . Pain-associated brain areas process sensory input and generate the perception of pain and adjunct emotions [13, 14] . Pain-related central networks are altered through an increase of synaptic connections and the stabilization of (preexisting) synaptic connections [15, 16] . Plastic changes in the CNS are based on longterm potentiation mechanisms. So recurrent acute pain secondarily leads to the manifestation of chronic pain and changes in central structures [16, 17] . However, peripheral mechanisms are also involved in chronic pain conditions caused by peripheral inflammation and the recurrence of acute pain episodes [18] [19] [20] . One of these peripheral changes has been described as visceral hypersensitivity [9, 16, 17] .
Previous studies have shown that noninvasive brain stimulation targeting pain-related central plastic changes reduces pain and leads to increased excitability in the primary motor cortex (M1) [21] [22] [23] [24] . Transcranial direct current stimulation (tDCS) is a good method to treat abdominal pain through M1 activation as it has been shown in several pain conditions such as pelvic pain, fibromyalgia, and spinal cord injury [7, 19, 21, 22, 25] . The underlying subcortical mechanisms of tDCS, as it is known from studies in animals and humans, can increase or decrease the neuronal resting membrane threshold depending on stimulation polarity [26] [27] [28] . Moreover, tDCS can modulate neuronal plasticity and strengthen synaptic transmission [26] . It is believed that tDCS mediates analgesic effects through modulation and changes in excitability in pain-related neuronal networks such as the thalamus [8, 29, 30] . Imaging studies support the notion that the activity of the thalamus is decreased through corticothalamic pathways, which leads to a decreased pain perception [31, 32] .
In light of these, we hypothesized that repeated sessions (10 sessions) of tDCS over M1 would relieve visceral pain in patients with HCC, and therefore we conducted a preliminary trial to test the effectiveness of this form of treatment in those patients.
Methods

Study Design and Eligibility
This randomized, double-blind, sham-controlled, prospective study was conducted at the pain clinic of Assiut University Hospital in the period between April 2015 and February 2016. Assiut Medical School Ethical Review Board approved the study. It is registered at www.clinicaltrials.gov under number NCT02928237.
Written informed consent was obtained from all of the subjects after describing the nature of the intervention and the possibility of receiving sham stimulation. All patients age 18 years and older with chronic abdominal pain due to primary liver cancer or on top of cirrhosis that was resistant to medical treatment for at least two months or associated with significant adverse effects from medication were involved in this study. All patients were referred to the pain clinic from the hepatology department and had complained of abdominal pain lasting more than two months. We excluded patients with histories of chronic pain syndrome. We excluded patients with intracranial metallic devices or with pacemakers. We also excluded those with extensive myocardial ischemia and those known to have epilepsy.
Fifty-four patients with chronic abdominal pain due to liver cancer were evaluated for recruitment in the study and allocated into one of two groups (1:1 ratio) using closed-envelope randomization (real tDCS group and sham tDCS group). Forty patients completed the study (20 real patients and 20 sham patients). Figure 1 shows a flow chart of the patients. Most of the patients had liver cirrhosis, with variable clinical manifestations such as cachexia, jaundice, ascites, hepatomegaly, and/or splenomegaly, but all of them were free from hepatic encephalopathy. All of the patients were under the same analgesic regimen through the course of the study: tramadol hydrochloride 50 mg twice daily. At baseline, all patients were taught how to evaluate their own pain intensity using the verbal descriptor scale (VDS) [33] , where the patient puts a checkmark next to the phrase that best describes the current level of his pain (the most intense pain imaginable, extreme pain, severe pain, moderate pain, mild pain, slight pain, no pain), and the visual analogue scale (VAS) [34] , scored from 0 to 10 where 0 ¼ no pain and 10 ¼ the worst pain imaginable; any changes in depressive symptoms were evaluated using the Hamilton rating scale for depression (HAM-D) [35] as the patient answer questioner, and the assessor summed the scores from the first through the 17th item, where 0-7 ¼ normal, 8-13 ¼ mild depression, 14-18 ¼ moderate depression, 19-22 ¼ severe depression, and !23 ¼ very severe depression.
Randomization and Blindness
Randomized numbers in a 1:1 ratio were generated using appropriate software (www.randomization.com) to assign each participant to either the real or sham group. Opaque envelopes were prepared for the randomization process and sealed. Each patient was placed in the appropriate group after opening the corresponding sealed envelope. The allocation concealment was reached as no investigator (stimulators or assessors) was aware of treatment allocations; the investigators had no control over the order of patients randomized. Assessment of patients was done by a blind assessor without knowing the type of stimulation applied. During the entire treatment protocol time, one of the authors Transcranial Direct Current Stimulation for HCC Patients was supervising the blinding and randomization process.
tDCS Intervention tDCS was delivered using a battery-driven DC stimulator (neuroConn Gmbh, 98693 llmenau, Germany). The electrodes were placed into a 35 cm 2 sponge immersed in saline solution 1% for better current conductivity. The electrodes attached to the scalp were sustained by a rubber band. The anode was placed over the primary motor cortex of the contralateral hemisphere of the most painful abdominal area; an EEG 10/20 system [36] was used to determine the primary motor area (M1) of the patient, and the cathode was placed over the opposite supraorbital region. In the active stimulation condition, a constant current of 2 mA intensity was applied for 30 minutes based on previous study [37] . In the sham stimulation condition, the machine was activated for 30 seconds using identical parameters but was then switched off without the patient's knowledge. The treatment was repeated every day for five consecutive days per week for two weeks (the total number of sessions given was 10 sessions). Each session was administered by a research professional experienced in tDCS treatment; the provider was not involved in patient assessment and was blinded to treatment allocation.
Follow-up Measures
Measurements were done at baseline (prestimulation) and after the first, fifth, and 10th sessions, then one month later, with all rating scales: VDS, VAS, and HAM-D. The measurements were done by a blind assessor who did not know the type of stimulation applied.
Outcomes
The primary outcome was pain relief on the VAS and VDS after the 10th session and one month later, and the secondary outcomes were depression reduction on HAM-D after the 10th session and one month later and the following side effects due to tDCS: mild headache, itching, scalp burning sensation, and skin redness.
Sample Size Method and Statistical Analysis
Sample size estimation was determined based on a previous clinical trial assessing the neuroplastic effects of tDCS on painful symptom reduction in chronic hepatitis C, with sample size of 28 patients divided into two groups (14 per group) in order to detect a 1.5 cm reduction in VAS level intensity (average SD ¼ 0.8 cm) with a power of 0.8 [38] . To account for the multiple outcomes and dropouts, we increased the sample size to 20 per group.
The values for each scale were analyzed separately by one way analysis of variance (ANOVA) repeated measures analysis (time "pre, first, fifth, 10th, and after one month" Â group "real and sham"). The data were tested for normality using the Anderson-Darling test and for homogeneity variances prior to further statistical analysis. Categorical variables were described by number and percent (No., %), and continuous variables were described by mean and standard deviation (mean, SD). Chi-square and Fisher's exact tests were used to compare between categorical variables, and continuous variables were compared by t test and one-way and twoway ANOVA. A P value of less than 0.05 was considered statistically significant. The percentage of reduction in each scale was calculated after the 10th session and one month after the end of stimulation as (((prestimulation score -poststimulation score) x 100)/prestimulation score), and then the two groups were compared using the Mann-Whitney test. All analyses were performed with IBM SPSS 20.0 software.
Results
Demographic and Clinical Characteristics of the Patients
Demographic/clinical data and different rating scales of assessment at the baseline are demonstrated in Table 1 , showing no statistically significant difference between studied groups as regards these data. Figure 2 and Table 2 show the effect of tDCS on pain rating scales (VAS and VDS) and how score at baseline changed over the following month. A two-way repeated measures ANOVA with TIME (prestimulation, at the first, fifth, and 10th day, and after one month of stimulation) and GROUP (real or sham) as the main factors showed a significant TIME Â GROUP interaction for VAS (P ¼ 0.001, F ¼ 6.817) and for VDS (P ¼ 0.001, F ¼ 4.01). This indicates that the effect of treatment differed in the two groups.
Primary Outcome Measurements
We then used a one-way ANOVA to examine the effect of TIME on the data from each group separately. There was a significant effect of time in both rating scales in the real group (P ¼ 0.001) and in the sham group (VAS P ¼ 0.002, VDS P ¼ 0.048). Thus both real and sham treatments tended to reduce symptoms. However, the effects were greater with real stimulation than with sham stimulation, particularly at the end of treatment and after one month. The results of individual t test comparisons between groups at each time point in comparison with the baseline assessment are shown in Figure 2 . In general, there was no effect of real tDCS after the first treatment session. A difference with the sham group gradually appeared over the course of treatment and was present at one-month follow-up. Percent changes in rating are shown in Table 3 . There was a significant percentage reduction in the scales after the 10th sessions (VAS P ¼ 0.001, VDS P ¼ 0.008) and one month after the end of stimulation (VAS P ¼ 0.037, VDS P ¼ 0.001). Figure 2 and Table 2 show the effect of tDCS on HAM-D and how score at baseline changed over the following month. A two-way repeated measures ANOVA with TIME (prestimulation, at the first, fifth, and 10th day, and after one month of stimulation) and GROUP (real or sham) as the main factors showed a significant TIME Â GROUP interaction for P ¼ 0.012 (F ¼ 5.077). This indicates that the effect of treatment differed in the two groups.
Secondary Outcome Measurements
We then used a one-way ANOVA to examine the effect of TIME on the data from each group separately. There was a significant effect of time on the HAM-D scale in the real group (P ¼ 0.001) and in the sham group (HAM-D P ¼ 0.001). Thus both real and sham treatments tended to reduce symptoms. However, the effects were greater with real stimulation than with sham stimulation, particularly at the end of treatment and after one month. The results of individual t test comparisons between groups at each time point in comparison with the baseline assessment are shown in Figure 2 . In general, there was no effect of real tDCS after the first treatment session. A difference with the sham group gradually appeared over the course of treatment and was present at one-month follow-up. Percent changes in rating are shown in Table 3 . There was a significant percentage reduction in the HAM-D scale after the 10th sessions (P ¼ 0.001) and one month after the end of stimulation (P ¼ 0.002).
No serious side effects related to tDCS treatment occurred in either group. In the real tDCS group, only three patients reported a slight burning sensation under the active electrode, and two patients complained of skin redness under the active electrode. These were temporary and did not require a change in treatment.
Discussion
Pain management in hepatically impaired patients is difficult owing to a lack of evidence-based guidelines for the use of analgesics in this population. Complications are more likely to occur with nonsteroidal antiinflammatory drugs, the pharmacokinetic parameters of paracetamol are altered, and the disposition of a large number of opioid drugs is affected [39] . So pain management becomes a great challenge in patients with cancer liver, usually on top of cirrhosis.
In a previous study, we tested the use of 30 mg morphine (MST) in a group of patients with liver cancer, and we reported a three-to fourfold increase in the peak concentration of morphine, presumably as a result of the reduction in first-pass metabolism secondary to a reduction in liver cell mass; this led to an increase in the total systemic bioavailability of morphine. Approximately 70% of the dose entered the systemic circulation in patients compared with 20% in healthy controls. Also, the side effects were more frequent, especially respiratory depression [40] .
In another trial, we studied the pharmacokinetic profile of oral tramadol 50 mg capsules in liver carcinoma patients who showed prolonged half-life, delayed clearance, and a high bioavailability of tramadol in comparison with healthy volunteers. The safety and efficacy of analgesia suggest the suitability of this drug in liver cancer with a lengthened dosing interval (to 12 hours) and with no respiratory depression; however, side effects like constipation were a problem, and certainly at a terminal stage, a huge variability might be expected [41] .
When our patients failed to respond well to tramadol 50 mg or developed side effects, this made us try an add-on effect. We shifted to noninvasive brain stimulation that may offer alternative therapeutic options for our patients. Several researchers have become interested in the use of these methods for the treatment of neuropsychiatric disorders, including chronic pain, depression, and migraine [42] .
As shown in our previous trial, which studied the efficacy of rTMS in 34 patients suffering from malignant visceral pain, 10 sessions of rTMS over the M1 could relieve malignant visceral pain for at least 15 days [43] , and similar results appeared when we used rTMS on another 34 patients with malignant neuropathic pain, where real rTMS had greater improvement in pain scales that persisted up to 15 days [44] .
Our results showed a decrease in pain scores (VDS and VAS) in both the sham and real groups, with greater improvement of pain and more prolonged effect up to one month in the real group, while the effect ended after only five days in the sham group. There was also an improvement in Hamilton rating scale for depression in both groups, which continued for one month of stimulation in the real group, and for only 10 days in the sham group. tDCS modulates excitability during as well as up to hours after the end of stimulation, depending on the duration and intensity of stimulation [42] . Liebetanz et al. revealed that the after-effects of anodal tDCS require a depolarization of membrane potentials. A combination of glutamatergic and membrane mechanisms is necessary to induce the after-effects of tDCS. So the changes in post-tDCS cortical excitability are intimately dependent on the Naþ channel and NMDA receptor activity [45] .
Our group was the first to consider repetitive transcranial magnetic stimulation (rTMS) in patients with central and peripheral neuropathic pain and its long-lasting antalgic effects, where rTMS produced long-lasting pain relief for two weeks after the treatment [46] .
One interesting study evaluated the effect of (2 mA, 20 minutes, five consecutive days, M1 target) of tDCS for reducing pain due to spinal cord injury, and the cumulative analgesic effects lasted up to two weeks after stimulation [21] . The same protocol was adopted in two studies with fibromyalgia, and a significant improvement in pain was detected following active tDCS [22, 47] . In one of these studies, the pain relief effects lasted up to three weeks [22] . Another study using tDCS to reduce myofascial pain [48] was able to reduce the pain symptoms and the effects that persisted one week after the final tDCS session.
Another interesting study investigated the effect of a different strategy of brain stimulation, which is 10 sessions of tDCS, 2 mA for 20 minutes every other day for four weeks in chronic migraine patients, which showed positive but delayed response. The effect started to appear after 30 days, and pain levels continued to decrease until the last follow-up after four months [49] .
On the other hand, a study evaluated the effectiveness of tDCS (2 mA, 20 minutes, five consecutive days) in chronic low back pain and showed that tDCS was ineffective for reduction of pain [50] .
The aim of the above studies using repeated sessions was to obtain more sustained relief with cumulative effect.
Prolonged placebo effect in the sham group up to five days is an interesting finding in our study; it may be due to increased duration of the session to 30 minutes. Also, expectation may be higher in cancer patients. The placebo mechanism is mediated by both opioid and nonopioid (endo cannabinoid) mechanisms. This effect could shed new light on mind-body interactions [51] . Other reasons could be related to the Hawthorne effect [52] or altering levels of hormones [53] . Another study speculated that tDCS is not only an analgesic method that triggers placebo response like other methods of analgesia, but also, it increases the placebo response [54] .
DosSantos et al. [55] investigated in vivo the involvement of the endogenous m-opioid system in the global tDCS analgesia experience. Placebo and real anodal primary motor cortex (M1/2mA) tDCS were delivered The figure shows changes in the verbal descriptor scale (A), the visual analog score (B), and the Hamilton rating scale-depression (C) in patients with malignant visceral pain at six points of assessment. The first one was prior to commencing transcranial direct current stimulation treatment (prestimulation). The second was after the first session (post-first session). The third was after the fifth session (post-fifth session), the fourth was after the 10th session of stimulation (post-10th session), and the fifth assessment points were at one month after the end of stimulation sessions. Data are expressed as mean 6 standard deviation.
Table 2
Rating scales of patients with visceral pain in studied groups (20 patients for each group; data presented as mean 6 SD)
Rating Scales They found that the analgesic effects reported with M1-tDCS can be in part related to the recruitment of the same endogenous MOR mechanisms induced by placebo and that such effects can be purposely optimized by real tDCS.
Another study explored the neurochemical action of tDCS in the fibromyalgia brain using proton magnetic resonance spectroscopy (1H-MRS). 1H-MRS is able to measure brain metabolite levels including c-aminobutyric acid (GABA), the brain's major inhibitory neurotransmitter, Glx, a combined marker of glutamine and glutamate (the latter being the brain's major excitatory neurotransmitter), and N-acetylaspartate (NAA), thought to be a measure of neuronal integrity. It showed that both the sham and active tDCS phases of the trial resulted in significant alterations in the brain metabolites for various pain centers in the brain [56] .
This view can explain the difference between sham and real groups in this trial. It seems that tDCS is a good inducer of placebo response, and the difference between patients is dependent on their level of expectation.
Few case reports about the use of tDCS in cancer patients with satisfying analgesic effects and improvement in depression scales have appeared in the literature; Nguyen et al. described a case study of metastatic bladder cancer uncontrolled by strong opioids and pregabalin. They used tDCS (1 mA, 20 minutes, five days) on the left motor cortex. Pain started to decrease by the second day of treatment. Drug treatment was decreased on the fifth day. The patient rapidly became less depressed and drowsy [57] .
In another case report, a 65-year-old female with pancreatic cancer received sham and active tDCS in a randomized order. It showed that active tDCS can acutely alleviate pain [58] .
Another case showed that tDCS improved cognitive outcomes in a cancer survivor with chemotherapyinduced cognitive difficulties [59] .
In agreement with our study, another recent study evaluated the efficacy of tDCS on 28 subjects with chronic hepatitis C who were randomized to receive either active or sham tDCS (2 mA, 20 minutes, five days, M1) to control painful symptoms related to pegylated interferon alpha (Peg-IFN). It showed improvement in pain scores, enhanced brain-derived neurotrophic factor (BDNF) levels, and reduced analgesic use, starting at the second session until the end of the treatment [38] .
The mechanisms underlying the analgesic effects elicited by tDCS are not fully understood yet, and the exact nature of the involved pathways remains hypothetical. Probable mechanisms are the changes of the resting membrane potential under the active electrode and remote effects in other parts of the pain processing network created by functional interconnections between motor cortex-driven inhibition of the somatosensory cortex and changes in thalamic activity. Brain stimulation with weak direct current modulates neuroplasticity of the human cerebral cortex and acetylcholine plays an important role in the consolidation of this neuroplasticity [60] . Anodal stimulation increases excitability, and cathodal stimulation reduces it. Inducing an intracerebral current flow stimulation changes EEG patterns and evoked potentials at the cortical level in humans. It induces focal, prolonged, reversible shifts of cortical excitability [42] . Furthermore, anodal stimulation was shown to induce an increase of endogenous opioid release [61] .
And as we mentioned before, tDCS is an easy device to apply and carries almost no risk. It may be possible to design tDCS devices for home use so that patients can use the device for extended durations at little or no extra cost.
Limitations
One of the limitations of this study is that the add-on effect cannot be excluded as patients took medications that could have analgesic effect that could interact with brain stimulation, and the small number of sessions is considered another limitation to this study. Regarding blindness, although the literature is still unclear as to whether participants themselves are able to differentiate between 2 mA active stimulation and placebo treatment, it has been found that redness of the skin is a possible clue for researchers to differentiate between the two [62, 63] . It is important that these results stem from crossover studies, in which subtle differences between treatments and the effects on each individual participant 0.002** * means significant P value ** means highly significant P value attract more attention. In a study with large sample of patients with a depression disorder using a parallel design that investigated tDCS blinding of 2 mA stimulation comparing between active or placebo treatment, Brunoni et al. [64] showed that patients were able to identify 2 mA active treatments above chance level, but this appeared to be related to the occurrence of clinical response. Patients who did not show clinical response to treatment were not able to identify active treatment.
Knowing if a parallel design has advantages for the accuracy of blinding in tDCS operators is important to assessing the reliability of results from double-blind studies using placebo-controlled tDCS in parallel designs [65] . In another point of view, Wallace et al. [66] investigated using 2 mA current strength over 30 minutes, tDCS stimulation comfort was lower at stimulation onset in young and older adults and, overall, lower for young participants. Investigators and participants may be able to identify active stimulation at above-chance levels, although accuracy never exceeded 65% for either participants or the experimenter.
Conclusions
This study demonstrates that a regimen of 10 daily sessions of 2 mA, 30 minutes, M1 target tDCS, in a group of patients with visceral pain due to HCC induces analgesic response that appears at the fifth session, with long-lasting effects for one month. The placebo effect seems to be a good analgesic response induced by tDCS.
